AbbVie registers Phase 3 trial of telisotuzumab adizutecan in NSCLC
New study will compare the ADC to standard chemotherapy in previously treated, EGFR wildtype non-squamous lung cancer with high c-Met expression.
This week brought a single new registration from AbbVie's oncology pipeline.
- AbbVie registered a Phase 3 trial (NCT07821684) of telisotuzumab adizutecan, an investigational drug, in adults with previously treated, EGFR wildtype, locally advanced or metastatic non-squamous NSCLC expressing high c-Met protein. The study is not yet recruiting1 and will compare the drug against standard of care, consisting of Docetaxel or Docetaxel with Ramucirumab1, with around 660 participants enrolled at approximately 250 sites worldwide1. Primary outcomes include objective response by blinded independent central review and overall survival, and the study is estimated to start on 2027-01-06 with primary completion in 2031-04.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.